Lapatinib Ditosylate Monohydrate CAS 388082-78-8 Purity >99.0% (HPLC)

Short Description:

Chemical Name: Lapatinib Ditosylate Monohydrate

CAS: 388082-78-8

Purity: >99.0% (HPLC)

Appearance: Pale Yellow to Yellow Crystalline Powder

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Lapatinib Intermediates:

Lapatinib Base	CAS 231277-92-2
Lapatinib Ditosylate Monohydrate	CAS 388082-78-8
Sodium Methanesulfinate	CAS 20277-69-4
3-Chloro-4-(3-Fluorobenzyloxy)aniline	CAS 202197-26-0
2-Aminoethyl Methyl Sulfone Hydrochloride	CAS 104458-24-4
4-Chloro-6-Iodoquinazoline	CAS 98556-31-1
6-Iodo-4-Hydroxyquinazoline	CAS 16064-08-7
5-Formyl-2-Furanboronic Acid	CAS 27329-70-0
5-[4-[3-Chloro-4-(3-Fluorobenzyloxy)anilino]-6-Quinazolinyl]furan-2-Carboxaldehyde	CAS 231278-84-5

Chemical Properties:

Chemical Name	Lapatinib Ditosylate Monohydrate
Synonyms	N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
CAS Number	388082-78-8
Stock Status	In Stock
Molecular Formula	C29H26ClFN4O4S·2(C7H8O3S)·H2O
Molecular Weight	943.48
COA & MSDS	Available
Origin	Shanghai, China
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Pale Yellow to Yellow Crystalline Powder
Purity / Analysis Method	≥99.0% (HPLC)
Melting Point	240.0~242.0℃
Moisture (K.F)	1.9~2.4%
Single Impurity	≤0.50%
Total Impurities	≤1.00%
Heavy Metals (as Pb)	≤20ppm
Test Standard	Enterprise Standard
Usage	API; For the treatment of patients with breast cancer

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

388082-78-8 - Application:

Lapatinib Ditosylate Monohydrate (CAS: 388082-78-8) is the ditosylate salt of CAS 231277-92-2, a synthetic, orally-active quinazoline with potential antineoplastic activity. It reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types. It was launched for the treatment of advanced or metastatic HER2 (ErbB2) positive breast cancer in women who have received prior therapy. The drug was discovered and developed by GlaxoSmithKline.